MaxCyte Inc at William Blair Growth Stock Conference Transcript
Good morning, everyone. Thanks for joining us for the final day of conference here, really pleased to have MaxCyte here presenting. My name is Matt Larew I cover MaxCyte for William Blair. Doug Doerfler, who is a Co-Founder, President, and CEO of the company will be presenting. Before we go into the presentation, two things, the breakout session is in Jenny B and then for a complete list of our disclosures, you can go to williamblair.com. Again very pleased to have MaxCyte here with us today. And with that, I will turn it over to Doug.
Thank you, Matt, and good morning, everyone. I'd like to thank the Blair team and thank you all for coming this morning. Sorry.
So we're listed on both the AIM in London and also Nasdaq. So please refer to our written statements.
Let me start off by saying that MaxCyte and our team are involved in enabling the majority of the advanced non-viral cell therapies in the clinic today. So we are
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |